March 18, 2021
Tag: Cellular Immunotherapy
March 4, 2021
Engineered safety switch curbs severe side effects of CAR-T immunotherapy
As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.
January 25, 2021
European Medicines Agency awards priority designation for Hodgkin lymphoma CAR-T therapy
The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.
January 6, 2021
Pharmacy Times: Study Suggests Way to Boost Immunotherapy Against Breast Cancer, Other Solid Tumors
January 4, 2021
Fierce Biotech: Research Putting the ‘STING’ on CAR-T cells to turn them against breast cancer and other solid tumors
January 4, 2021
Drug Target Review: Activating STING enhances CAR T-cell activity in solid tumours, shows study
December 31, 2020
United Press International: Study: Modified immunotherapy may work in advanced breast cancer
September 9, 2020
Immuno-Oncology News: Strong Response for Tessa’s CD30 CAR-T Cell Therapy in Hodgkin’s Lymphoma Trial
August 6, 2020
Targeted Oncology: Autologous CAR T-Cell Therapy Induces Durable Responses in Relapsed/Refractory Hodgkin Lymphoma
August 6, 2020